| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c7bc2db915943032735e0165932fabe |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
1997-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d17195ca9f52117f713541094d385a6 |
| publicationDate |
1997-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2242775-A1 |
| titleOfInvention |
1-arylphthalazine antagonists of excitatory amino acid receptors |
| abstract |
Substituted 1-arylphthalazine compositions such as formula (1) are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtypes of the ionotropic EAA receptors. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compositions may be provided in combination with a suitable pharmaceutical carrier for therapeutic administration for the treatment of a variety of disorders associated with non-NMDA EAA receptor function. The compositions may be used, for example, as sedatives or for the treatment of neuropsychopharmacological disorders such as stroke, ischemia, epilepsy and mood disorders. |
| priorityDate |
1996-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |